Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 3
Submit an article Journal homepage
193
Views
50
CrossRef citations to date
0
Altmetric
Review

Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity

Michaela AdamcováCharles University in Prague Faculty of Medicine, Department of Physiology, Šimkova 870, 500 38, Hradec KrálovéCzech RepublicTel: +420 49 5816180; Fax: +420 49 5436054;E-mail: [email protected]
,
Martin ŠterbaCharles University in Prague Faculty of Medicine, Department of Pharmacology, Šimkova 870, 500 38, Hradec KrálovéCzech Republic
,
Tomáš ŠimunekCharles University in Prague Faculty of Pharmacy, Department of Biochemical Sciences, Heyrovskeho 1203, 500 05, Hradec KrálovéCzech Republic
,
Anna PotácováCharles University in Prague Faculty of Medicine, Department of Histology and Embryology, Šimkova 870, 500 38, Hradec KrálovéCzech Republic
,
Olga PopelováCharles University in Prague Faculty of Medicine, Department of Physiology, Šimkova 870, 500 38, Hradec KrálovéCzech RepublicTel: +420 49 5816180; Fax: +420 49 5436054;E-mail: [email protected]
,
Yvona MazurováCharles University in Prague Faculty of Medicine, Department of Pharmacology, Šimkova 870, 500 38, Hradec KrálovéCzech Republic
&
Vladimír GeršlCharles University in Prague Faculty of Pharmacy, Department of Biochemical Sciences, Heyrovskeho 1203, 500 05, Hradec KrálovéCzech Republic
 show all
Pages 457-472 | Published online: 10 May 2005

Bibliography

  • CASARETT LJ, WATKINS JB, KLAASSEN CD, DOULL J: Toxic responses of the heart and vascular systems. In: Casarett & Doull "S Toxicology - The Basic Science of Poisons (5th edition). Klaassen CD (Ed.), McGraw-Hill Professional, New York (1998):487–500.
  • GHARIB MI, BURNETT AK: Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur. I Heart Fail. (2002) 4(3):235–242.
  • YEH ETH, TONG AT, LENIHAN DJ et al.: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation (2004) 109(25):3122–3131.
  • TOMITA S, ISHIDA M, NAKATANI T et al.: Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy. J. Heart Lung Transplant. (2004) 23(5):577–584.
  • KARMEN A, WROBLEWSKI F, LADUE JS: Transaminase activity in human blood. J. Clin. Invest. (1954) 34:126–133.
  • PANTEGHINI M, APPLE FS, CHRISTENSON RH, DATI F, MAIR J, WU AH: Proposals from the IFCC Committee on markers of cardiac damage (C-SMCD): recommendations on the use of biochemical markers of cardiac damage in acute coronary syndromes. Scan J. Clin. Lab. Invest. (1999) 59(230):103–112.
  • JOINT EUROPEAN SOCIETY OF CARDIOLOGY/AMERICAN COLLEGE OF CARDIOLOGY COMMITTEE: Myocardial infarction redefined - a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J. Am. Coll Cardiol. (2000) 36:959.
  • MISSOV E, CALZOLARI C, PAU B: Circulating cardiac troponin I in severe congestive heart failure. Circulation (1997) 96:2953–2958.
  • MAIR J: Progress in myocardial damage detection: New biochemical markers for clinicians. Grit. Rev Cl. Lab. Sci. (1997) 34(1):1–66.
  • LA VECCHIA L, MEZZENA G, OMETTO R et al.: Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am. J. Cardiol. (1997) 80:88.
  • WALLACE KB, HAUSNER E, HERMAN E et al: Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol. Foam]. (2004) 32:106–121.
  • ••Review about the cardiac markerscontaining the data about biology of troponins.
  • EBASHI S, ENDO M, OHTSUKI I: Control of muscle contraction. Q. Rev. Biophys. (1969) 2:351–384.
  • GREASER ML, YAMAGUCHI M, BREKKE C, POTTER J, GERGELY J: Troponin subunits and their interactions. Cold Spring Harbour Symp. Quant. Biol. (1972) 37:235–244.
  • PERRY SV: Troponin I: Inhibitor or facilitator. Mol. Cell. Biochem. (1999) 190:9–32.
  • SOLARO RJ: Troponin C - troponin I interactions and molecular signalling in cardiac myofilaments. Adv. Exp. Med. Biol. (1995) 382:109–115.
  • SOLARO RJ, RARICK HM: Troponin and tropomyosin: Proteins that switch on and tune in the activity of cardiac myofilaments. Circ. Res. (1998) 83:471–480.
  • WILKINSON JM, GRAND RJA: Comparison of amino acid sequence of troponin I from different striated muscles. Nature (1978) 271:31–35.
  • PEARLSTONE J, CARPENTER M, SMILLIE L: Amino acid sequences of rabbit cardiac troponin T. J. Biol. Chem. (1986) 261:16795–16810.
  • PHARMACEK MS, LEIDEN JM: Structure, function and regulation of troponin C. Circulation (1991) 84:991–1003.
  • HOLT DW: Pm-clinical application of markers of myocardial damage. In: Myocardial damage. Developments in Cardiovascular Medicine (vol. 205). Kaski JC and Holt DW (Eds.) Kluwer Academic Publishers (1998):201–210.
  • WU AHB: Role of serum biochemical markers in clinical trials. In: Myocardial damage. Developments in Cardiovascular Medicine (vol. 205). Kaski JC and Holt DW (Eds.), Kluwer Academic Publishers (1998):189–198.
  • SPARANO JA, WOLFF AC, BROWN DL: Troponins for predicting cardiotoxicity from cancer therapy. Lancet (2000) 356(9246):1947–1948.
  • SPARANO JA, BROWN DL, WOLFF AC: Predicting cancer therapy-induced cardiotoxicity - The role of troponins and other markers. Drug Sal: (2002) 25(5):301–311.
  • ••Review about the utility of biomarkersincluding natriuretic peptides.
  • HERMAN EH, FERRANS VJ: The use of cardiac biomarkers for the detection of drug-induced myocardial damage. In: Markers in Cardiology. Current and future clinical applications. Adams JE III, Apple FS, Jaffe AS, Wu AHB (Eds.) Armonk, NY, Futura Publishing Company, Inc. (2001) 211–234.
  • ••Review about the utility of biomarkersto detect cardiotoxic effects in pharmacological studies.
  • HERMAN EH, LIPSHULTZ SE, FERRANS VJ: The use of cardiac markers to detect myocardial damage induced by chemotherapeutic agents. In: Cardiac Markers. Wu AHB (Ed.) Humana Press, Inc., Totowa, NJ (2003):87–109.
  • ••Review about the utility of biomarkers todetect cardiotoxic effects of antineoplastics agents.
  • TOWNSEND PJ, FARZA H, MACGEOCH C et al.: Human cardiac troponin T identification of fetal isoforms and assignment of the TNNT2 locus to chromosome 1 q. Cenomics (1994) 21:311–316.
  • VALLINS WJ, BRAND NJ, DABHADE N, BUTLER-BROWNE G, YACOUB MH, BARTON PJR: Molecular cloning of human cardiac troponin I using polymerase chain reaction. FEBS Lett. (1990) 270:57–61.
  • SASSE S, BRAND NJ, KYPRIANOU P et al Troponin I gene expression during human cardiac development and in endstage heart failure. Circ. Res. (1993) 72:932–938.
  • RICCHIUTI V, VOSS EM, NEY A, ODLAND M, ANDERSON PAW APPLE FS: Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. OM Chem. (1998) 44:1919–1924.
  • BODOR GS, SURVANT L, VOSS EM, SMITHS, PORTERFIELD D, APPLE FS: Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin. Chem. (1997) 43(3):476–484.
  • DEAN KJ: Biochemistry and molecular biology of troponin I and T. In: Cardiac Markers. Wu AHB (Ed.), Humana Press, Inc., Totowa, NJ (1998):193–204.
  • VOSS EM, SHARKEY SW, GERNERT AE et al: Human and canine cardiac troponin T and creatine kinase MB distribution in normal and diseased myocardium: Infarct sizing using serum profiles. Arch. Athol Lab. Med. (1995) 119:799–806.
  • WU AHB: Markers of ischemia. In: Cardiac Markers. Wu AHB (Ed.), Humana Press, Inc., Totowa, NJ (2003):250–271.
  • ••Leading international authorities describethe state-of-the-art uses of cardiac markers.
  • KATUS HA, REMPPIS A, NEUMANN FJ et al: Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation (1991) 83:902–912.
  • KATUS HA, REMPPIS A, SCHEFFOLD T, DIEDERICH KH, KUBLER W: Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am. J. Cardiol (1991) 67:1360–1367.
  • MAIR J, GENSER N, MORANDELL D: Cardiac troponin I in the diagnosis of myocardial injury and infarction. Clin. Chim. Acta (1996) 245:19–38.
  • MAIR J, WAGNER I, PUSCHENDORF B et al Cardiac troponin I to diagnose myocardial injury. Lancet (1993) 341:838–839.
  • O'BRIEN PJ, DAMERON GW, BECK ML et al.: Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab. AlliM. Science (1997) 47(5):486–495.
  • O'BRIEN PJ, DAMERON GW, BECK ML et al: Differential reactivity of cardiac and skeletal muscle from various species in two generations of cardiac troponin immunoassays. Res. Vet. Sci. (1998) 65(2):135–137.
  • FREDERICKS S, MERTON GK, LERENA MJ, HEINING P, CARTER ND, HOLT DW: Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. Clin. Chim. Acta (2001) 304:65–74.
  • CALABRESI P, CHABNER BA: Chemotherapy of neoplastic diseases. In: Goodman Gilman's The pharmacological bash of therapeutics (10th edition). Hardman JG, Limbird LE (Eds.), New York: McGraw-Hill (2001):1381–1459.
  • TAN C, TASAKA H, YU KP, MURPHY ML, KARNOFSKY DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer (1967) 20:333–353.
  • VON HOFF DD, ROZENCWEIG M, PICCART M: The cardiotoxicity of anticancer agents. Senna Oncol (1982) 9:23–33.
  • HRDINA R, GERSL V, KLIMTOVA I, SIMUNEK T, MACHACKOVA J, ADAMCOVA M: Anthracycline - induced cardiotoxicity. Acta medica (Hradec Kralove) (2000) 43(3):75–82.
  • STEINHERZ LJ, STEINHERZ PG, TAN CT, HELLER G, MURPHY ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (1991) 266: 1672-1677.
  • SEINO Y, TOMITA Y, NAGAE Y et al:Cardioprotective effects of ACE-inhibitor (Cilazapril) on adriamycin cardiotoxicity in spontaneously hypertensive rats. Circulation (1993) 88:1633.
  • HERMAN EH, ZHANG J, LIPSHULTZ SE et al.: Correlation between serum levels of cardiac troponin T and severity of the chronic cardiomyopathy induced by doxorubicin. I Clin. Oncol. (1999) 17(7):2237–2243.
  • HERMAN EH, LIPSHULTZ SE, RIFAI N et al.: Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. (1998) 58(2):195–197.
  • GERSL V, HRDINA R: Noninvasive polygraphic changes in daunorubicin-induced cardiomyopathy in rabbits. Sbor. vet/. prat!'" LF UK Hradec Kralove (1994) 37(2)49–55.
  • ADAMCOVA M, GERSL V, HRDINA R et al.: Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. ./. Cancer Res. Clin. Oncol. (1999) 125(5):268–274.
  • SIMUNEK T, KLIMTOVA I, KAPLANOVA J et al: Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur. J. Heart Failure (2004) 6:377–387.
  • SIMUNEK T, KLIMTOVA I, ADAMCOVA M et al: Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. Cancer Chemother. Pharmacol. (2003) 52:431–434.
  • KOH E, NAKAMURA T, TAKAHASHI H: Troponin T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ. J. (2004) 68 (2):163–167.
  • HERMAN EH, FERRANS VJ: Preclinicalanimal models of cardiac protection from anthracycline-induced cardiotoxicity. Semi]. Oncol. (1998) 25:15–21.
  • BERTINCHANT JP, POLGE A, JUAN JM et al.: Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy in rats, and their relationship with echocardiographic and histological findings. Clin. Chim. Acta (2003) 329(1-2).39–51.
  • ADAMCOVA M, GERSL V, MACHACKOVA J et al.: Troponins in experimental studies. Acta medica (Hradec Kralove) (2002) 45(1):29–32
  • GENSER N, FINK FM, MAIR J, DENGG K, ELLENMUTER H, PUSCHENDORF B: Plasma concentration of creatine kinase MB mass and troponin T in children receiving anthracycline chemotherapy. Clin. Chem. (1993) 39:1170a.
  • RADERER M, KORNEK G, WEINLANDER G, KASTNER J: Serum troponin T levels in adults undergoing anthracycline therapy./. Nat. Cancer Inst. (1997) 89(2):179.
  • FINK FM, GENSER N, FINK CH, FALK M, MAIR J: Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med. Pediam Oncol. (1995) 25:185–189.
  • KISMET E, VARAN A, AYABAKAN C, ALEHAN D, PORTAKAL 0, BUYUKPAMUKCU M: Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr. Blood Cancer (2004) 42(3):220–224.
  • LIPSHULTZ SE, RIFAI N, SALLAN SE et al: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 96:2641–2648
  • AUNER HW, TINCHON C, LINKESCH W et al: Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol (2003) 82(4):218–222.
  • MATHEW P, SUAREZ W, KIP K et al: Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest. (2001) 19:352–359.
  • SEDKY LM, HAMADA E, SELIM H et al: The value of troponin I measurement in assessment of anthracycline induced cardiotoxicity among breast cancer patients. Proc. Am. Soc. Clin. Oncol (2001) 20:6b.
  • CARDINALE D, SANDRI MT, MARTINONI A et al: Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll Cardiol. (2000) 36:517–522.
  • MISSOV E, CALZOLARI C, DAVY JM, LECLERCQ F, ROSSI M, PAU B: Cardiac troponin I in patients with hematologic malignancies. Cor. Artery Dis. (1997) 8:537–541.
  • CARDINALE D, SANDRI MT, COLOMBO A et al: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation (2004) 109(22):2749–2754.
  • LIPSHULTZ SE, SALLAN S, DALTON V et al.: Elevated serum cardiac troponin T as a marker for active cardiac injury during therapy for childhood acute lymphoblastic leukemia (ALL). Proc. Am. Soc. Clin. Oncol. (2001) 18:568a.
  • LIPSHULTZ SE, RIFAI N, DALTON VM et al.: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl. I Med. (2004) 351:145–153.
  • LINK G, TIROSH R, PINSON A, HERSHKO C: Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. (1996) 127(3):272–278.
  • HERMAN EH, ZHANG J, RIFAI N et al.: The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. (2001) 48:297–304.
  • ADAMCOVA M,• GERSL V, MACHACKOVA J, HRDINA R, KLIMTOVA I, SIMUNEK T: Troponins for predicting cardiotoxic or cardioprotective effects of new drugs. In: Advances in recent cardiovascular research - Proceedings of the 22nd European section Meeting of ISHR Szeged (Hungary). VarrO A, Végh A (Eds.), Monduzzi Editore, Italy (2002):87–91.
  • ADAMCOVA M,• PELOUCH V, GERSL V et al.: Protein profiling in daunorubicin-induced cardiomyopathy. Gen. Physiol. Biophys. (2003) 22(3):411–419.
  • ADAMCOVA M,• MACHACKOVA J, GERSL V et al.: Cardiac troponin T following repeated administration of pyridoxal isonicotinoyl hydrazone in rabbits. Phys. Res. (2002) 51(5):443–448.
  • SIMUNEK T, KLIMTOVA I, KAPLANOVA J et al: Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol. Res. (2005) 51:223–231.
  • FELESZKO W, MLYNARCZUK I, BALKOWIEC-ISKRA EZ et al: Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res. (2000) 6(5):2044–2052.
  • WISEMAN LR, SPENCER CM: Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs (1998) 56:385–403.
  • ARLIN ZA, SILVER R, CASSILETH P et al.: Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat. Rep. (1985) 69:61–64.
  • DE FORNI M, MALET-MARTINO MC, JAILLAIS P et al.: Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J. Clin Oncol (1992) 10:1795–1801.
  • OZTOP I, GENCER M, OKAN T et al: Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracilifolinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jap.Oncol (2004)34(5):262–268.
  • NAG SM, BRISCOE K, DESOUZA P: A pilot study of troponin T as a prognostic marker in patients treated with 5-fluorouracil. Proc. Am. Soc. Clin. Oncol (2001) 20:344b.
  • GOLDBERG MA, ANTIN JH, GUINAN EC, RAPPEPORT JM: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood (1986) 68:1114–1118.
  • AUNER HW, TINCHON C, BREZINSCHEK RI et al.: Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Europ. Haematol (2002) 69(1):1–6.
  • BENVENUTO GM, LA VECCHIA L, MORANDI P et al: Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors. Ital. Heart J. (2000) 1:1457–1463.
  • MORANDI P, RUFFINI PA, BENVENUTO GM, LA VECCHIA L, MEZZENA G, RAIMONDI R: Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7g/m2) cyclophosphamide. Bone Marrow Transpl. (2001) 28(3):277–282.
  • MACHACKOVA J, ADAMCOVA M, GERSL V, HRDINA R, MAZUROVA Y, NOBILIS M: Evaluation of cardiac effects of the new antineoplastic drug - dimethoxybenfluron - on a rabbit model. Phys. Res. (2001) 50:491–499.
  • DELLA TORE P, PODESTA A, IMONDI AR et al.: PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Cancer Chemother. Pharmacol (2001) 47(4):355–360.
  • FLECKENSTEIN A, JANKE V, DORING HJ: Myocardial fiber necrosis due to intracellular Ca overload, a new perception in cardiac pathophysiology. In: Myocardial biology. Dhalla NS (Ed.), Baltimore University Press, Baltimore (1974):563–580.
  • BLEUEL H, DESCHL U, BERTSCH T et al: Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage. Exp. Toxicol Pathol (1995) 47:121–127.
  • BERTSCH T, BLEUEL H, AUFENANGER J, REBEL W: Comparison of cardiac troponin T and cardiac troponin I concentrations in peripheral blood during orciprenaline induced tachycardia in rats. Exp. Toxicol Pathol (1997) 49:467–468.
  • ADAMCOVA M, KOKSTEIN Z, PALICKA V et al.: Cardiac troponin T in pregnant women having intravenous tocolytic therapy. Arch. Gynecol Obstet. (1999) 62:121–126.
  • ADAMCOVA M, KOKSTEIN Z, PALICKA V, VAVROVA J, PODHOLOVA M, KOSTAL M: Cardiac troponin T in neonates after acute and long-term tocolysis. Biol. Neonate (2000) 78(4):281–287.
  • LECHNER W, ARTNER DWORZAK E, SOLDER E: Tocolysis with magnesium, hexoprenalin-metoprolol and diltiazem - evaluation of cardiotoxic side-effects during troponin T. Magnesium-Bull. (1992) 14(1):12–14.
  • CHIANG VW, BURNS JP, RIFAI N, LIPSHULTZ SE, ADAMS MJ, WEINER DL: Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: A prospective assessment. J. Pediatr. (2000) 137(1):73–77.
  • PEDERSON KJ, KUNTZ DH, GARBE GJ: Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man. Gonad. Cardiol (2001) 17(5):599–601.
  • PATEL VB, AJMAL R, SHERWOOD RA, SULLIVAN A, RICHARDSON PJ, PREEDY VR: Cardioprotective effect of propranolol from alcohol-induced heart muscle damage as assessed by plasma cardiac troponin T. Alcohol. Clin. Exp. Res. (2001) 25(6):882–889.
  • DENISON H, JERN S, JAGENBURG R, WENDESTAM C, WALLERSTEDT S: ST-segment changes and catecholamine-related myocardial enzyme release during alcohol withdrawal. Alcohol Alcoholism (1997) 32(2):185–194.
  • MCLEURIN M, APPLE FS, HENRY TD et al.: Cardiac troponin I and T concentrations in patients with cocaine-associated chest pain. Ann. Clin. Biochem. (1996) 33:183–186.
  • KONTOS MC, ANDERSON FP, ORNATO JP, TATUM JL, JESSE RL: Utility of troponin I in patients with cocaine-associated chest pain. Acad. Emerg. Med. (2002) 9:1007–1013.
  • ERWIN MB, DELIARGYRIS EN: Cocaine-associated chest pain. Am. J. Med. Sri. (2002) 324(1):37–44.
  • KATUS HA, REMPPIS A, LOOSER S, HALLERMEIER K, SCHEFFOLD T, KUBLER W: Enzyme-linked immunoassay of cardiac troponin T for detection of acute myocardial infarction in patients. J. MoL Cardiol (1989) 21:1349–1353.
  • LARUE C, DEFACQUE- LACQUEMENT H, CALZOLARI C, LE NGUYEN D, PAU B.: New monoclonal antibodies as probes for human cardiac troponin I: Epitopic analysis with synthetic peptides. Mol. Immunol (1992) 29:271–278.
  • LAURINO JP: Troponin I: An update on clinical utility and method standartization. An. Clin. Lab. Science (2000) 30(4):412–421.
  • KATUS HA, LOOSER S, HALLERMAYER K et al: Development and in vitro characterization of a new immunoassay for cardiac troponin T. Clin. Chem. (1992) 38:386–393.
  • COLLINSON PO, BOA FG, GAZE DC: Measurement of cardiac troponins. Ann. Biochem. (2001) 38(5):423–449.
  • ••Review about current commerciallyavailable assays.
  • WU AHB: Analytical issues affecting the clinical performance of cardiac troponin assays. In: Markers in cardiology: Current and future clinical applications. Adams JE III (Ed.), Futura Publishing Company, Inc., Armonk, NY (2001):1–12.
  • ••The book provides a concise and informative summary.
  • VALDES R Jr., JORTANI SA: The current assessment of qualitative and quantitative point-of-care testing of cardiac markers. In: Markers IP cardiology: Current and future clinical applications. Adams JE III (Ed.), Futura Publishing Company, Inc., Armonk, NY (2001):35–46.
  • PANTEGHINI M, PAGANI F, BONETTI G: The sensitivity of cardiac markers: An evidence-based approach. Clin. Chem. Lab. Med. (1999) 37(11/12):1097–1106.
  • WU AHB, APPLE FS, GIBLER WB, JESSE RL, WARSHAW MM, VALDES R Jr: National Academy of Clin. Biochem. Standards of Laboratory Practise: Recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. (1999) 45:1104–1121.
  • MORJANA NA: Degeneration of human cardiac troponin I after myocardial infarction. Biotechnol Appl. Biochem. (1998) 28:105–111.
  • KATRUKHA AG, BEREZNIKOVA AV, ESAKOVA TV et al.: Troponin I is released in blood stream of patients with acute myocardial infarction not in free form but as a complex. Clin. Chem. (1997) 43:1379–1385.
  • TATE JR, HEATHCOTE D, RAYFIELD J, HICKMAN PE: The lack of standardization of cardiac troponin I assay systems. Clin. aim. Acta (1999) 284(2):141–149.
  • APPLE FS, QUIST HE, DOYLE PJ, OTTO AP, MURAMAKI MM: Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology American College of Cardiology consensus recommendations. Clin. Chem. (2003) 49(8):1331–1336.
  • WU AHB: Analytical issues and the evaluation of cutoff concentrations for cardiac markers. In Cardiac Markers. Wu AHB (Ed.) Humana Press, Inc., Totowa, NJ (2003):231–241.
  • GAO WD, ATAR D, LIU YG, PEREZ NG, MURPHY AM, MARBAN E: Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ. Res. (1997) 80(3):393–399.
  • MCDONOUGH JL, ARRELL DK, VAN EYK JE: Troponin I degradation and covalent complex formation accompanies myocardial ischemiaireperfusion injury. Circ. Res. (1999) 84(1):9–20.
  • HERMENS WTH: Mechanisms of protein release from injured heart muscle. In: Myocardial damage. Developments IP Cardiovascular Medicine (vol. 205). Kaski JC and Holt DW (Eds.), Kluwer Academic Publishers (1998):189–198.
  • MAIR J: Tissue release of cardiac markers: From physiology to clinical applications. Clin. Chem. Lab. Med. (1999) 37(11/ 12):1077–1084.
  • VAN DER LAARSE A: Hypothesis: Troponin degradation is one of the factors responsible for deterioration of left ventricular function in heart failure. Cardiovasc. Res. (2002) 56(1):8–14.
  • JAFFE AS, RAVKILDE J, ROBERTS R et al.: It's time for a change to a troponin standard. Circulation (2000) 102:1216–1220.
  • REMPPIS A, SCHEFFOLD T, GRETEN J et al: Intracellular compartmentation of troponin T: release kinetics after global ischemia and calcium paradox in the isolated perfused rat heart. Mol Cell. Cardiol (1995) 27(2):793–803.
  • CHILDS AC, PHANUEF SL, DIRKS AJ, PHILLIPS T, LEEUWENBURGH C: Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bc1-2 : Box ratio. Cancer Res. (2002) 62(16):4592–4598.
  • CHRISTIANSEN S, REDMANN K, SCHELD HH et al: Adriamycin-induced cardiomyopathy in the dog - an appropriate model for research on partial left ventriculectomy. J. Heart Lung Transpl. (2002) 21:783–790.
  • JAFFE AS: Elevations in cardiac troponin measurements: false false-positives. The real truth. Cardiovasc. Toxicol (2001) 1:87–92.
  • NOSANCHUK JS: False increases of troponin I attributable to incomplete separation of serum. Clin. Chem. (1999) 45:714.
  • PLEBANI M, MION M, ALTINIER S, GIROTTO MA, BALDO G, ZANINOTTO M: False-positive troponin I attributed to a macrocomplex. Clin. Chem. (2002) 48:677–678.
  • GERHARDT W, NORDIN G, HERBERT AK et al: Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. Clin. Chem. (2000) 46:817–821.
  • STIEGLER H, FISCHER Y, VAZQUEZ-JIMENEZ JF et al: Lower cardiac troponin T and I results in heparin-plasma than in serum. Clin. Chem. (2000) 46:1338–1344.
  • KATRUKHA A, BEREZNIKOVA A, FILATOV V, ESAKOVA T: Biochemical factors influencing measurement of cardiac troponin I in serum. Clin. Chem. Lab. Med. (1999) 37(11/12):1091–1095.
  • NOUSIAINEN T, JANTUNEN E, VANNINEN E et al: Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur. Haematol (1999) 62:135–141.
  • SUZUKI T, HAYASHI D, YAMAZAKI T et al: Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. (1998) 136:362–363.
  • HAYAKAWA H, KOMADA Y, HIRAYAMA M et al: Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med. Pediatr. Oncol. (2001) 37:4–9.
  • DUNN MJ: Studying heart disease using the proteomic approach. Drug Discov. Today (2000) 5:76–84.
  • LABUGGER R, ARRELL DK, VAN EYK JE: Cardiac troponins: Exploiting the diagnostic potential of disease-induced protein modifications. In Cardiac Markers. Wu AHB (Ed.) Humana Press, Inc., Totowa, NJ (2003):125–138.
  • PETRIOCIN EF, RAJAPASKE V, HERMAN EH et al: Toxicoproteomics: Serum proteomics pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicol Pathol (2004) 32(1):122–130.

Websites

  • http://www.fda.gov/ohrms/dockets/ac/02/ briefing/ 3891B1_01_Troponin.Outline.pdf. NICE website press release (2002) Expert working group on biomarkers of drug-induced cardiac toxicity: Report to the Nonclinical Studies Subcommittee of the Advisory Committee for Pharmaceutical Science.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.